Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis

Nephrology Dialysis Transplantation

Volumn 17, Issue 12, 2002, Pages 2077-2080

  Staegeman, Coen A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; Microscopic polyangiitis; Myeloperoxidase; Proteinase 3; Small vessel vasculitis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEROXIDASE; SERINE PROTEINASE;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; SMALL VESSEL VASCULITIS; TREATMENT FAILURE; FOLLOW UP; FORECASTING; IMMUNOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FOLLOW-UP STUDIES; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELOBLASTIN; PEROXIDASE; RECURRENCE; SERINE ENDOPEPTIDASES; TREATMENT FAILURE; VASCULITIS;

EID: 0036899113     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429
2. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-1657
3. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753
4. Savage CO. ANCA-associated renal vasculitis. Kidney Int 2001; 60: 1614-1627
5. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
6. Gordon M, Luqmani RA, Adu D et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-789
7. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39
8. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-430
9. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88: 127-133
10. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37: 219-228
11. Kyndt X, Reumaux D, Bridoux F et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 527-533
12. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-389
13. Gaskin G, Savage CO, Ryan JJ et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6: 689-694
14. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32
15. Cohen Tervaert JW, Goldschmeding R, Elema JD et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37: 799-806
16. Stegeman CA, Cohen Tervaert JW, Sluiter WJ et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17
17. Girard T, Mahr A, Noel LH et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology 2001; 40: 147-151
18. Ara J, Mirapeix E, Rodriguez R, Saurina A, Darnell A. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999; 14: 1667-1672
19. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-2033
20. Slot MC, Boomsma MM, Kallenberg CGM, Cohen Tervaert JW, Stegeman CA. A positive PR3-ANCA titer at switch to azathioprine therapy is associated with a disquieting relapse rate in ANCA-related vasculitis. Clev Clin J Med 2002; 69(Supp] 2): SII-175.
21. Cohen Tervaert JW, van der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-2465
22. Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-371
23. Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711
24. Nowack R, Grab I, Flores-Suarez LF et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001; 16: 1631-1637
25. Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Antineutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15
26. Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14: 15-22
27. Chang L, Binos S, Savige J. Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies. Clin Exp Immunol 1995; 102: 112-119
28. Griffith ME, Coulthart A, Pemberton S, George AJ, Pusey CD. Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol 2001; 123: 170-177
29. van der Geld YM, Simpelaar A, Van Der ZR et al. Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides. Kidney Int 2001; 59: 147-159
30. Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990; 82: 244-249
31. Chan TM, Frampton G, Jayne DR et al. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993; 22: 387-392
32. Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995; 15: 201-207
33. Gisslen K, Wieslander J, Westberg G, Herlitz H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Intern Med 2002; 251: 129-135